Alan F. List, MD, on the CC-5013-MDS-005 Study

2014 ASH Annual Meeting

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 409, “Efficacy and Safety of Lenalidomide vs Placebo in RBC Transfusion–Dependent Patients With IPSS Low-/Intermediate-Risk Myelodysplastic Syndromes Without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents: Results From a Randomized Phase III Study (CC-5013-MDS-005),” presented by Valeria Santini, MD.

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormalities in Myelofibrosis: Molecular and Phenotypic Correlates in 826 Patients;” abstract 406, “Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis;” and abstract 405, “Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project.”

Leukemia

Lymphoma

Julie M. Vose, MD, MBA, FASCO

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma,” presented by Matthew A. Lunning, DO.

Hematologic Malignancies

Keith McCrae, MD

May

Today In Oncology

Alan F. List, MD, on the CC-5013-MDS-005 Study

Related Videos

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

BPDCN FDA Approves Pivekimab Sunirine-pvzy

After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention

Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

Early Breast Cancer Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy